Description

PT-141 Research Grade Compound Handbook Product Overview

PT-141 (bumenopeptide) is a selective melanocortin receptor agonist that preferentially targets MC-4R and MC-1R receptors, enhancing sexual arousal by regulating the hypothalamic limbic system neural circuit. Phase IIb clinical trials have confirmed its significant therapeutic effect on female sexual dysfunction disorder (HSDD), improving subjective arousal scores by up to 40%. In addition, the peptide exhibits hemostatic potential in acute bleeding models by activating platelet alpha 2-adrenergic receptors (mechanism independent of traditional coagulation pathways), resulting in a 35% reduction in bleeding time. As a structurally optimized derivative of melatonin 2 (MT-2), PT-141 retains its core active site but removes its function of promoting melanin production, focusing on neuroendocrine regulation. It is now expanding its application in intervention research for traumatic stress and neuropsychiatric disorders

main features
·   High purity: HPLC verification purity ≥ 99%
·   Research focus: PT-141 is an agonist of melanocortin-4 receptor and melanocortin-1 receptor. Research has shown that it can promote sexual arousal and stimulate the immune system.
·   Appearance: Peptide in freeze-dried (powder) form
·   Packaging specification: 10mg standard packaging (can be customized according to requirements)
·   Cold chain transportation: Ensure temperature throughout the entire process (-20 ℃)

Disclaimer: The waiver shall ensure that:
Comply with the laboratory’s “Regulations on the Management of Hazardous Chemicals” and local regulations
Established compound lifecycle tracking system
Any consequences resulting from authorized resale or non scientific use shall be borne by the user themselves